摘要
目的:观察复方血栓通胶囊治疗急性中心性浆液性脉络膜视网膜病变(CSC)的临床疗效和安全性。方法:急性CSC患者83例(83眼)随机分为观察组42例(42眼)和对照组41例(41眼)。对照组给予口服维生素E软胶囊0.1g,qd,维生素C片0.2g,tid,维生素B1片10mg,tid;,观察组在对照组治疗基础上加用复方血栓通胶囊1.5g,po,tid。持续服用2个月,比较两组临床疗效、治愈时间、视力恢复时间、药品不良反应以及治疗前后视力、光学相干断层扫描技术(OCT)检查结果变化;随访3个月,比较两组复发率。结果:观察组总有效率为90.5%,显著高于对照组的26.8%(P<0.05)。观察组治疗1,4,8周后视力均明显优于对照组(P<0.05),治愈时间、视力恢复时间也显著短于对照组(P<0.05)。治疗后,两组黄斑中心区直径1mm范围的厚度、黄斑中心区直径6mm的平均厚度和黄斑中心区直径6mm的总体积均较治疗前显著降低(P<0.05),且观察组明显低于对照组(P<0.05)。随访3个月,观察组复发率明显低于对照组(P<0.05)。两组患者均未发生药品不良反应。结论:复方血栓通胶囊治疗急性CSC能显著提高疗效,且安全性较好。
Objective ： To investigate the efficacy and safety of Compound Xueshuantong capsule for acute central serous chorioretinopathy （CSC）. Methods：Totally 83 patients （83 eyes） who suffered acute CSC were divided into two groups randomly. The treatment group included 42 cases （42 eyes）, and the control group 41 cases （41 eyes）. The control group was given Vitamin E soft capsules 0. lg, qd, Vitamin C tablets 0.2g, tid, and Vitamin Bl tablets 10mg, tid. Based the above treatment, treatment group was given Compound Xueshuantong capsule 1.5g, rid additionally. The treatment courses were two months. The curative effect, healing time, visual recovery time, ADR and the OCT results of two groups were compared. The recurrence rate of two groups were compared at 3 months follow-up. Results ： After treatment, the total effec- tive rate in treatment group was 90.5%, which was significantly higher than 26.8% in the control group（P 〈 0.05）. After 1, 4, 8 weeks treatment, the vision was increased significantly in treatment group（P 〈 0.05）. Healing time, visual recov- ery time in treatment goup was significantly less than those in the control group（ P 〈 0.05 ）. Macular center thickness of 1 mm diameter range, the average thickness of the macular area of 6 mm diameter and the diameter and the central area and the total macular volume of both group were significantly lower than before（ P 〈 0.05 ）, and the treatment group was much lower than the control group. At 3 months follow-up, the recurrence rate of treatment group was significantly lower than the control group（ P 〈 0.05 ）. No significant ADR was observed in two groups. Conclusion： Compound Xueshuantong capsule could significantly improve the efficacy in the treatment of acute central serous chorioretinopathy, and it had good safety.
出处
《药物流行病学杂志》
CAS
2017年第11期742-744,785,共4页
Chinese Journal of Pharmacoepidemiology
